{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:02:18Z","timestamp":1790337738827,"version":"4.1.0"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007352","name":"Staatssekretariat f\u00fcr Bildung, Forschung und Innovation","doi-asserted-by":"publisher","award":["22.00119"],"award-info":[{"award-number":["22.00119"]}],"id":[{"id":"10.13039\/501100007352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["GA 101057491"],"award-info":[{"award-number":["GA 101057491"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UKRI","doi-asserted-by":"publisher","award":["10042451"],"award-info":[{"award-number":["10042451"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejps.2026.107652","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:55:25Z","timestamp":1788364525000},"page":"107652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-5084","authenticated-orcid":false,"given":"Rasha A.","family":"Alshaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diarmuid J.","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyfrig A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona M.","family":"O\u2019Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107652_bib0028","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2026.107652_bib0033","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation: PATISIRAN (ONPATTRO \u2014 ALNYLAM NETHERLANDS BV). (2019a). https:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/complete\/SR0598%20Onpattro%20-%20CDEC%20Final%20Recommendation%20July%2029%2C%202019%20for%20posting.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0070","unstructured":"Alnylam Pharmaceuticals. Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMOTM (lumasiran). (2020). https:\/\/investors.alnylam.com\/press-release?id=25271 [Accessed October 4, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0158","doi-asserted-by":"crossref","unstructured":"Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, Gallagher E, Chand M, Brown K, Ladhani SN, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv (2021)2021.09.15.21263583. doi: 10.1101\/2021.09.15.21263583.","DOI":"10.1101\/2021.09.15.21263583"},{"key":"10.1016\/j.ejps.2026.107652_bib0011","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40273-020-00956-w","article-title":"Recalibrating health technology assessment methods for cell and gene therapies","volume":"38","author":"Angelis","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ejps.2026.107652_bib0155","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2026.107652_bib0050","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2026.107652_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101386","article-title":"Optimizing regulatory frameworks for gene therapies in rare diseases: Challenges and solutions","volume":"32","author":"Berry","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ejps.2026.107652_bib0115","unstructured":"Biogen. QALSODY\u00ae (tofersen) \u2013 Support and Resources. https:\/\/www.qalsody.com\/en-us\/home\/support-and-resources.html [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0108","unstructured":"Biogen Canada Inc. Product Monograph Including Patient Medication Information (SPINRAZA; Nusinersen injection). (2017). https:\/\/www.biogen.ca\/content\/dam\/corporate\/americas\/canada\/en-ca\/medicines\/spinraza\/SPINRAZA_PM_EN.pdf [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2024.09.001","article-title":"Good practices for health technology assessment guideline development: a report of the health technology assessment international, htasialink, and ispor special task force","volume":"28","author":"Botwright","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.ejps.2026.107652_bib0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40273-024-01433-4","article-title":"Managed entry agreements for high-cost, one-off potentially curative therapies: a framework and calculation tool to determine their suitability","volume":"43","author":"Callenbach","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ejps.2026.107652_bib0149","unstructured":"Canada\u2019s Drug Agency. REIMBURSEMENT RECOMMENDATION: Tofersen (Qalsody). (2025). https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2025\/SR0883-Qalsody-Recommendation.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0130","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH COMMON DRUG REVIEW: Pharmacoeconomic Review Report Inotersen (Tegsedi). (2020). https:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/sr0603-tegsedi-pharmacoeconomic-review-report.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0082","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Recommendation: Lumasiran (Oxlumo) 2. (2023a). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2023\/SR0734%20Oxlumo%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20Final.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0145","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH COMMON DRUG REVIEW: Spinraza. (2019b). https:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/complete\/SR0576-Spinraza-Resubmission-Mar-1-19.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0111","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Drug Reimbursement Recommendation: INOTERSEN (TEGSEDI \u2014 AKCEA THERAPEUTICS, INC.). (2019c). https:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/complete\/SR0603%20Tegsedi%20-%20Final%20CDEC%20Recommendation%20December%2020%2C%202019%20for%20posting.pdf [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0046","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Common Drug Review, Pharmacoeconomic Review Report: Patisiran (Onpattro). (2019d). https:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/sr0598-onpattro-pharmacoeconomic-review-report.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0055","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Recommendation: Givosiran (Givlaari). (2021a). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/SR0679%20Givlaari%20-%20CADTH%20Final%20Rec-pw.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0068","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Review: Givosiran (Givlaari). (2021b). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/SR0679-Givlaari%20combined-meta.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0114","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Recommendation: Nusinersen (Spinraza). (2022a). https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2022\/SR0713-Spinraza-Reassessment.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0144","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Review: Nusinersen (Spinraza). (2022b). https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2022\/SR0713-Spinraza-Reassessment.pdf [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0083","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Review: Lumasiran (Oxlumo). (2023b). https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2023\/SR0734-Oxlumo.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0096","unstructured":"Canadian Agency for Drugs and Technologies in Health. Reimbursement Review Inclisiran (Leqvio). (2024a). https:\/\/cda-amc.ca\/sites\/default\/files\/DRR\/2024\/SR0791-Combined_Review.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0097","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Recommendation: Inclisiran (Leqvio). (2024b). https:\/\/cadth.ca\/sites\/default\/files\/DRR\/2024\/SR0791-000REC-Leqvio_HeFH.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0103","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Reimbursement Recommendation: Vutrisiran (Amvuttra). (2024c). https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2024\/SR0801REC-Amvuttra%20Final.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0131","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023895","article-title":"Navigating the complex web of prescribing amyloidosis therapeutics: a primer","volume":"11","author":"Chen","year":"2022","journal-title":"J. Am. Heart Assoc.: Cardiovasc. Cerebrovasc. Dis."},{"key":"10.1016\/j.ejps.2026.107652_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: a novel Frontier in pharmacological strategy","volume":"14","author":"Collotta","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107652_bib0010","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10198-020-01212-w","article-title":"HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies","volume":"21","author":"Coyle","year":"2020","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.ejps.2026.107652_bib0167","series-title":"CADTH Health Technology Review Cost-Effectiveness of Respiratory Syncytial Virus Vaccines for Adults","author":"Crawford","year":"2024"},{"key":"10.1016\/j.ejps.2026.107652_bib0169","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","article-title":"Managed entry agreements: policy analysis from the European perspective","volume":"23","author":"Dabbous","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.ejps.2026.107652_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejps.2026.107652_bib182","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/s12887-022-03671-x","article-title":"Advances and limitations for the treatment of spinal muscular atrophy","volume":"22","author":"Day","year":"2022","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.ejps.2026.107652_bib0014","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/hematology.2024000663","article-title":"Givosiran: a targeted treatment for acute intermittent porphyria","volume":"2024","author":"Dickey","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ejps.2026.107652_bib0168","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12913-023-09494-5","article-title":"How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?","volume":"23","author":"Drummond","year":"2023","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.ejps.2026.107652_bib0113","doi-asserted-by":"crossref","DOI":"10.52965\/001c.24934","article-title":"The antisense oligonucleotide nusinersen for treatment of spinal muscular atrophy","volume":"13","author":"Edinoff","year":"2021","journal-title":"Orthop. Rev."},{"key":"10.1016\/j.ejps.2026.107652_bib0013","unstructured":"European Medicines Agency. Onpattro: EPAR product information. (2018). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/onpattro-epar-product-information_en.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0026","unstructured":"European Medicines Agency. mResvia (single-stranded 5\u2032-capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilised in the prefusion conformation): an overview of mResvia and why it is authorised in the EU. (2025). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mresvia-epar-medicine-overview_en.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0024","unstructured":"European Medicines Agency. Comirnaty (raxtozinameran, bretovameran, mRNA encoding KP.2): EPAR product information. (2020a). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/comirnaty-epar-product-information_en.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0154","unstructured":"European Medicines Agency. EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU | European Medicines Agency (EMA). (2021a). https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-covid-19-vaccine-moderna-authorisation-eu [Accessed April 5, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0025","unstructured":"European Medicines Agency. Spikevax (elasomeran; elasomeran\/imelasomeran; elasomeran\/davesomeran; andusomeran): EPAR product information. (2021b). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spikevax-epar-product-information_en.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0053","unstructured":"European Medicines Agency. Assessment report: Givlaari, INN-givosiran. (2020b). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/givlaari-epar-public-assessment-report_en.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0022","unstructured":"European Medicines Agency. Qalsody | European medicines agency (EMA). (2024) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qalsody [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0001","series-title":"Medical Device Innovation Handbook","article-title":"Reimbursement basics","author":"Finch","year":"2024"},{"key":"10.1016\/j.ejps.2026.107652_bib0052","article-title":"FDA approves givosiran for acute hepatic porphyria","year":"2019","journal-title":"Food and Drug Administration"},{"key":"10.1016\/j.ejps.2026.107652_bib0152","doi-asserted-by":"crossref","DOI":"10.15190\/d.2021.1","article-title":"First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization","volume":"9","author":"Fortner","year":"2021","journal-title":"Discoveries"},{"key":"10.1016\/j.ejps.2026.107652_bib0029","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-art and future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejps.2026.107652_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.1052625","article-title":"Lumasiran for primary hyperoxaluria type 1: what we have learned?","volume":"10","author":"Gang","year":"2023","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ejps.2026.107652_bib0002","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jval.2016.02.012","article-title":"Health technology assessment for molecular diagnostics: practices, challenges, and recommendations from the medical devices and diagnostics special interest group","volume":"19","author":"Garfield","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.ejps.2026.107652_bib0100","unstructured":"Gemeinsamer Bundesausschuss. Justification of the resolution of the federal joint committee (G-BA) on an Amendment of the Pharmaceuticals Directive: Annex XII \u2013 Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Vutrisiran (Hereditary transthyretin-mediated amyloidosis with polyneuropathy (stage 1 or 2)). (2023). https:\/\/www.g-ba.de\/downloads\/40-1465-9413\/2023-04-06_AM-RL-XII_Vutrisiran_D-877_TrG_EN.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0035","article-title":"Benefit assessment of drugs with new active ingredients according to \u00a7 35a SGB V Evaluation of orphan medicinal products in accordance with Section 35a (1) sentence 11 in conjunction with Chapter 5 \u00a7 12 No. 1 sentence 2 VerfO Active substance","author":"Gemeinsamer","year":"2019","journal-title":"Patisiran"},{"key":"10.1016\/j.ejps.2026.107652_bib0036","unstructured":"Gemeinsamer Bundesausschuss. Underlying reasons on the decision of the Joint Federal Committee on an amendment to the Medicinal Products Directive (AM-RL): Annex XII-Decisions on the benefit assessment of medicinal products with new active substances pursuant to Section 35a SGB V-Patisiran. (2019b). www.g-ba.de."},{"key":"10.1016\/j.ejps.2026.107652_bib0125","unstructured":"Gemeinsamer Bundesausschuss. Underlying reasons on the decision of the Federal Committee Joint on an amendment to the Medicinal Products Directive (AM-RL): Annex XII-Decisions on the benefit assessment of medicinal products with new active substances according to \u00a7 35a SGB V-Inotersen. (2019c). https:\/\/www.g-ba.de\/downloads\/40-268-5646\/2019-03-22_AM-RL-XII_Inotersen_D-381_TrG.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0126","unstructured":"Gemeinsamer Bundesausschuss. Resolution of the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL) Annex XII \u2013 Benefit assessment of medicinal products with new active ingredients pursuant to Section 35a SGB V: Inotersen. (2019d). https:\/\/www.g-ba.de\/downloads\/39-261-3717\/2019-03-22_AM-RL-XII_Inotersen_D-381_BAnz.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0127","unstructured":"Gemeinsamer Bundesausschuss. Summarizing documentation on an amendment to the Medicinal Products Directive (AM-RL): Annex XII-Decisions on the benefit assessment of medicinal products with new active substances according to \u00a7 35a SGB V (Inotersen). (2019e). https:\/\/www.g-ba.de\/downloads\/40-268-7440\/2019-03-22_AM-RL-XII_Inotersen_D-381_ZD.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0057","unstructured":"Gemeinsamer Bundesausschuss. Justification to the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII-Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V Givosiran (Acute Hepatic Porphyria, \u2265 12 Years). (2020a). https:\/\/www.g-ba.de\/downloads\/40-1465-6937\/2020-10-15_AM-RL-XII_Givosiran_D-536_TrG_EN.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0063","unstructured":"Gemeinsamer Bundesausschuss. Underlying reasons on the decision of the Federal Joint Committee on an amendment to the Medicinal Products Directive (AM-RL): Annex XII-Benefit assessment of medicinal products with new active substances according to \u00a7 35a SGB V Givosiran (acute hepatic porphyria,\u2265 12 years). (2020b). https:\/\/www.g-ba.de\/downloads\/40-268-6937\/2020-10-15_AM-RL-XII_Givosiran_D-536_TrG.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0064","unstructured":"Gemeinsamer Bundesausschuss. Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII-Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V Givosiran (Acute Hepatic Porphyria, \u2265 12 Years). (2020c). https:\/\/www.g-ba.de\/downloads\/39-261-4500\/2020-10-15_AM-RL-XII_Givosiran_D-536_BAnz.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0065","unstructured":"Gemeinsamer Bundesausschuss. Amendment on the benefit assessment of medicinal products with new active substances according to \u00a7 35a SGB V Evaluation of orphan medicinal products in accordance with Section 35a (1) sentence 11 in conjunction with Chapter 5 \u00a7 12 No. 1 sentence 2 VerfO Active substance: Givosiran. (2020d). https:\/\/www.g-ba.de\/downloads\/92-975-3851\/2020-10-15_Amendment_Givosiran_D-536.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0066","unstructured":"Gemeinsamer Bundesausschuss. Benefit assessment of drugs with new active ingredients according to \u00a7 35a SGB V Evaluation of orphan medicinal products in accordance with Section 35a (1) sentence 11 in conjunction with Chapter 5 \u00a7 12 No. 1 sentence 2 VerfO Active substance: Givosiran. (2020e). https:\/\/www.g-ba.de\/downloads\/92-975-3680\/2020-04-15_Nutzenbewertung-G-BA_Givosiran_D-536.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0074","unstructured":"Gemeinsamer Bundesausschuss. Amendment on the benefit assessment of medicinal products with new active substances according to \u00a7 35a SGB V Assessment of orphan medicinal products in accordance with Section 35a (1) sentence 11 in conjunction with Chapter 5 \u00a7 12 No. 1 sentence 2 VerfO Active substance: Lumasiran. (2021a). https:\/\/www.g-ba.de\/downloads\/92-975-4619\/2021-07-01_Amendment-G-BA_Lumasiran_D-622.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0076","unstructured":"Gemeinsamer Bundesausschuss. Justification of the Resolution of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII-Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Lumasiran (Hyperoxaluria). (2021b). https:\/\/www.g-ba.de\/downloads\/40-1465-7656\/2021-07-01_AM-RL-XII_Lumasiran_D-622_TrG_EN.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0077","unstructured":"Gemeinsamer Bundesausschuss. Resolution of the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL) Annex XII \u2013 Benefit assessment of medicinal products with new active ingredients pursuant to Section 35a SGB V: Lumasiran (Hyperoxaluria). (2021c). https:\/\/www.g-ba.de\/downloads\/39-261-4910\/2021-07-01_AM-RL-XII_Lumasiran_D-622_BAnz.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0079","unstructured":"Gemeinsamer Bundesausschuss. Summarizing documentation on an amendment to the Medicinal Products Directive (AM-RL): Lumasiran. (2021d). https:\/\/www.g-ba.de\/downloads\/40-268-8438\/2021-07-01_AM-RL-XII_Lumasiran_D-622_ZD.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0080","unstructured":"Gemeinsamer Bundesausschuss. Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V: Lumasiran. (2021e). https:\/\/www.g-ba.de\/downloads\/92-975-4349\/2021-01-01_Nutzenbewertung-G-BA_Lumasiran_D-622.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0093","unstructured":"Gemeinsamer Bundesausschuss. Justification of the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII \u2013 Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V Inclisiran (Primary hypercholesterolaemia or mixed dyslipidaemia). (2021f). https:\/\/www.g-ba.de\/downloads\/40-1465-7674\/2021-07-15_AM-RL-XII_Inclisiran_D-640_TrG_EN.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0094","unstructured":"Gemeinsamer Bundesausschuss. Resolution of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive (AM-RL) Annex XII-Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Inclisiran (Primary hypercholesterolaemia or mixed dyslipidaemia). (2021g). https:\/\/www.g-ba.de\/downloads\/39-1464-4922\/2021-07-15_AM-RL-XII_Inclisiran_D-640_EN.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0137","unstructured":"Gemeinsamer Bundesausschuss. Underlying reasons on the decision of the Joint Federal Committee on an amendment to the Medicinal Products Directive (AM-RL): Annex XII-Benefit assessment of medicinal products with new active substances according to \u00a7 35a SGB V Nusinersen (exceeding 50 million\u20ac limit: spinal muscular atrophy). (2021h). https:\/\/www.g-ba.de\/downloads\/40-1465-5749\/2019-05-16_AM-RL-XII_Nusinersen_D-294_TrG_EN.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0138","unstructured":"Gemeinsamer Bundesaussch. Internal Justification of the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII-Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Nusinersen (exceeding \u20ac50 million turnover limit: Spinal Muscular Atrophy). (2021i). https:\/\/www.g-ba.de\/downloads\/40-1465-7541\/2021-05-20_AM-RL-XII_Nusinersen_D-614_TrG_EN.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0139","unstructured":"Gemeinsamer Bundesausschuss. Summarizing documentation on an amendment to the Medicinal Products Directive (AM-RL): Annex XII-Benefit assessment of medicinal products with new active substances according to \u00a7 35a SGB V Nusinersen. (2021j). https:\/\/www.g-ba.de\/downloads\/40-268-8395\/2021-05-20_AM-RL-XII_Nusinersen_D-614_ZD.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0140","unstructured":"Gemeinsamer Bundesausschuss. Resolution of the Federal Joint Committee on an amendment to the Medicinal Products Directive (AM-RL): Annex XII-Benefit assessment of medicinal products with new active substances according to \u00a7 35a SGB V Nusinersen (exceeding 50 million\u20ac limit: spinal muscular atrophy). (2021k). https:\/\/www.g-ba.de\/downloads\/39-1464-3789\/2019-05-16_AM-RL-XII_Nusinersen_D-294_EN.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0038","unstructured":"Gemeinsamer Bundesausschuss. Justification: Patisiran. (2024a). https:\/\/www.g-ba.de\/downloads\/40-1465-10496\/2024-05-16_Patisiran_D-993_TrG_EN.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0119","unstructured":"Gemeinsamer Bundesausschuss. Tofersen (amyotrophic lateral sclerosis (ALS)) Resolution of 19 December 2024. (2024b). https:\/\/www.g-ba.de\/downloads\/91-1455-1094\/2024-12-19_Current-Version_Tofersen_D-1063_EN.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.pmbts.2023.12.022","article-title":"Types of RNA therapeutics","volume":"203","author":"Goleij","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.ejps.2026.107652_bib0163","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(24)00589-9","article-title":"Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial","volume":"25","author":"Goswami","year":"2025","journal-title":"Lancet Infect. Dis."},{"issue":"11","key":"10.1016\/j.ejps.2026.107652_bib183","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","article-title":"Clinical diagnosis and management of amyotrophic lateral sclerosis","volume":"7","author":"Hardiman","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejps.2026.107652_bib0043","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. EFFICIENCY NOTICE ONPATTRO (patisiran). (2019b). https:\/\/www.has-sante.fr\/jcms\/p_3082349\/en\/onpattro-11062019-avis-efficience [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0136","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. HAS-Medical and Economic Evaluation and Public Health Division: Nusinersen (SPINRAZA). (2020e). https:\/\/www.has-sante.fr\/jcms\/p_3229643\/en\/spinraza-22072020-summary-ct18244 [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0134","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. EFFICIENCY NOTICE: Spinraza\u00ae (nusinersen). (2017). https:\/\/www.has-sante.fr\/jcms\/c_2839849\/en\/spinraza-12122017-avis-efficience [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0135","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Nusinersen SPINRAZA 12 mg, solution for injection. (2020d). https:\/\/www.has-sante.fr\/jcms\/p_3199400\/en\/spinraza-22072020-avis-ct18244 [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0101","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. AMVUTTRA (vutrisiran) - Amylose h\u00e9r\u00e9ditaire \u00e0 transthyr\u00e9tine. (2023a) https:\/\/www.has-sante.fr\/jcms\/p_3402366\/en\/amvuttra-vutrisiran-amylose-hereditaire-a-transthyretine [Accessed October 5, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0042","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. COMMISSION DE LA TRANSPARENCE AVIS: Patisiran. (2019a). https:\/\/www.has-sante.fr\/jcms\/c_2912139\/en\/onpattro-20032019-avis-ct17388 [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0061","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. COMMISSION DE LA TRANSPARENCE AVIS: Givosiran. (2021a). https:\/\/www.has-sante.fr\/jcms\/p_3258963\/en\/givlaari-24032021-avis-ct19110 [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0071","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. COMMISSION DE LA TRANSPARENCE AVIS: Lumasiran, OXLUMO 94,5 mg\/0,5 mL, solution injectable. (2021b). https:\/\/www.has-sante.fr\/jcms\/p_3266577\/en\/oxlumo-pic-ins-avisdef-ct19056-epi726 [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0161","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. ECONOMIC OPINION: Spikevax. (2023d). https:\/\/www.has-sante.fr\/jcms\/p_3472171\/en\/spikevax-10102023-avis-economique [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0123","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. EFFICIENCY NOTICE: Tegsedi (Inotersen). (2019c). https:\/\/www.has-sante.fr\/jcms\/p_3082334\/en\/tegsedi-14052019-avis-efficience [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0124","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. TRANSPARENCY COMMITTEE OPINION SUMMARY: TEGSEDI (Inotersen). (2019d). https:\/\/www.has-sante.fr\/jcms\/p_3146211\/en\/tegsedi-summary-ct17282 [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0072","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. TRANSPARENCY COMMITTEE SUMMARY: Lumasiran, OXLUMO, 94.5 mg\/0.5 mL solution for injection. (2021c). https:\/\/www.has-sante.fr\/jcms\/p_3406289\/en\/oxlumo-210421-summary-ct19056-1 [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0034","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. HAS-Direction de l\u2019Evaluation M\u00e9dicale, Economique et de Sant\u00e9 Publique Final opinion: Patisiran, ONPATTRO 2 mg\/ml, solution for injection. (2020a). https:\/\/www.has-sante.fr\/jcms\/p_3146852\/en\/onpattro-08012020-avis-ct18250 [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0059","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. HAS-Direction de l\u2019Evaluation M\u00e9dicale, Economique et de Sant\u00e9 Publique Final opinion: Givosiran GIVLAARI 189 mg\/1 mL, solution injectable. (2020b). https:\/\/www.has-sante.fr\/jcms\/p_3191914\/en\/givlaari-24062020-avis-ct18608 [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0060","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Efficiency Notice: Givlaari (givosiran). (2020c). https:\/\/www.has-sante.fr\/jcms\/p_3223752\/en\/givlaari-15092020-avis-economique [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0159","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. SPIKEVAX dispersion for injection and dispersion for injection in pre-filled syringe. (2023b). https:\/\/www.has-sante.fr\/jcms\/p_3466352\/en\/spikevax-20092023-avis-ct20314 [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0160","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. SUMMARY: SPIKEVAX, dispersion for injection and dispersion for injection in pre-filled syringe. Initial inclusion. (2023c). https:\/\/www.has-sante.fr\/jcms\/p_3494157\/en\/spikevax-20092023-summary-ct20314 [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0089","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. First-time registration: Approval for reimbursement of LEQVIO (inclisiran) only for primary prevention in the treatment of adult patients with heterozygous familial hypercholesterolemia (HFHe). (2024a). https:\/\/www.has-sante.fr\/jcms\/p_3538268\/en\/leqvio-28082024-avis-ct20782 [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0090","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Transparency Committee Opinion summary: Inclisiran, LEQVIO, 284 mg solution for injection in a pre-filled syringe, First listing. (2024b). https:\/\/www.has-sante.fr\/jcms\/p_3588348\/en\/leqvio-280824-summary-ct20782 [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0133","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Advice on the medicine Nusinersen SPINRAZA 12 mg. (2024c). https:\/\/www.has-sante.fr\/jcms\/p_3529320\/en\/spinraza-03072024-avis-ct20615 [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0148","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Haute Autorit\u00e9 de Sant\u00e9 - QALSODY (tofersen) - Amyotrophic lateral sclerosis (ALS). (2024d) https:\/\/www.has-sante.fr\/jcms\/p_3561111\/en\/qalsody-tofersen-amyotrophic-lateral-sclerosis-als [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0157","unstructured":"Health Information and Quality Authority. Duration of protective immunity following COVID-19 vaccination (efficacy and effectiveness). (2021). https:\/\/www.hiqa.ie\/sites\/default\/files\/2021-12\/CV19_Vaccination_Underlying_Conditions.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0166","unstructured":"Health Information and Quality Authority. Protocol for a health technology assessment of immunisation against respiratory syncytial virus (RSV) in Ireland. (2025). https:\/\/www.hiqa.ie\/sites\/default\/files\/2025-01\/RSV-immunisation-protocol-infants-adults.pdf [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0132","unstructured":"Health Service Executive. Medicines Management Programme Managed Access Protocol-Nusinersen (Spinraza\u00ae) for the treatment of 5q Spinal Muscular Atrophy. (2023). https:\/\/www.hse.ie\/eng\/about\/who\/cspd\/medicines-management\/managed-access-protocols\/nusinersen-spinraza-\/managed-access-protocol-nusinersen-spinraza.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0032","unstructured":"Health Service Executive. Managed access protocol \u2013 medicines used in hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. (2024). https:\/\/assets.hse.ie\/media\/documents\/Medicines_in_hereditary_transthyretin_amyloidosis_in_adult_patients_w_stage_1o_RF2q9XA.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0116","unstructured":"Health Service Executive. Managed Access Protocols - HSE.ie. (2025) https:\/\/www.hse.ie\/eng\/about\/who\/cspd\/medicines-management\/managed-access-protocols\/[Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib181","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2147\/DDDT.S214174","article-title":"Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence","volume":"16","author":"Hjartarson","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejps.2026.107652_bib0007","first-page":"1","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejps.2026.107652_bib0128","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Dossier evaluation: Inotersen (hereditary transthyretin amyloidosis with polyneuropathy). (2018). https:\/\/www.g-ba.de\/downloads\/92-975-2643\/2018-10-01_Bewertung-Therapiekosten-Patientenzahlen-IQWiG_Inotersen-D-381.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0062","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Dossier evaluation Givosiran (acute hepatic porphyria)-Valuation according to \u00a7 Section 35a (1) sentence 11 SGB V Order: G20-07. (2020). https:\/\/www.iqwig.de\/download\/g20-07_givosiran_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0078","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Dossier evaluation Lumasiran (hyperoxaluria)-Valuation according to \u00a7 Section 35a (1) sentence 11 SGB V. (2021a). https:\/\/www.iqwig.de\/en\/projects\/g21-02.html [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0091","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Dossier evaluation: Inclisiran (primary hypercholesterolemia and mixed dyslipidemia)- Benefit assessment according to \u00a7 35a SGB V. (2021b). https:\/\/www.iqwig.de\/download\/a21-13_inclisiran_nutzenbewertung-35a-sgb-v_v1-0.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0092","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Inclisiran (primary hypercholesterolaemia or mixed dyslipidaemia) \u2013 Benefit assessment according to \u00a735a Social Code Book V1 :Translation of Sections 2.1 to 2.5 of the dossier assessment. (2021c). https:\/\/www.iqwig.de\/download\/a21-13_inclisiran_extract-of-dossier-assessment_v1-0.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0141","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Nusinersen (spinal muscular atrophy)-Addendum to order A20-114. (2021d). https:\/\/www.g-ba.de\/downloads\/92-975-4484\/2021-05-20_Addendum-IQWiG_Nusinersen_D-614.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0142","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Dossier evaluation Nusinersen (spinal muscular atrophy)-Benefit assessment according to \u00a7 35a SGB V. (2021e). https:\/\/www.iqwig.de\/download\/a20-114_nusinersen_nutzenbewertung-35a-sgb-v_v1-0.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0039","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Drug approval and early benefit assessment in Germany. (2026). https:\/\/www.iqwig.de\/en\/presse\/in-the-focus\/new-drugs-approval-benefit-assessment-coverage\/1-drug-approval-and-early-benefit-assessment-in-germany\/[Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0048","unstructured":"Institute for Clinical and Economic Review. A LOOK AT INOTERSEN AND PATISIRAN FOR HATTR. (2018). https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Amyloidosis_RAAG_10042018.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0146","unstructured":"Institute for Clinical and Economic Review. A LOOK AT SPINRAZA AND ZOLGENSMA FOR SPINAL MUSCULAR ATROPHY. (2019). https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/SMA-RAAG_060519.pdf [Accessed April 15, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0118","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). [G24-17] Tofersen (SOD1-associated amyotrophic lateral sclerosis) \u2013 Assessment according to \u00a735a (para. 1, sentence 11) Social Code Book V. (2024) doi: https:\/\/doi.org\/10.60584\/G24-17."},{"key":"10.1016\/j.ejps.2026.107652_bib0112","unstructured":"Ionis Pharmaceuticals Inc. Form 10-K Annual Report for the fiscal year ending December 31, 2024. (2025). https:\/\/www.sec.gov\/Archives\/edgar\/data\/874015\/000087401526000115\/form10k.htm [Accessed April 10, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0109","unstructured":"Ionis Pharmaceuticals. Akcea and Ionis Receive FDA Approval of TEGSEDI\u2122 (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults. (2018) https:\/\/ir.ionis.com\/news-releases\/news-release-details\/akcea-and-ionis-receive-fda-approval-tegseditm-inotersen [Accessed April 5, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0020","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2026.107652_bib0099","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2026.107652_bib0162","doi-asserted-by":"crossref","unstructured":"Kohli M, Maschio M, Joshi K, Lee A, Fust K, Beck E, Velde N Van de, Weinstein M. The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Fall 2023 vaccines in the United States. medRxiv (2023)2023.09.05.23295085. doi: 10.1101\/2023.09.05.23295085.","DOI":"10.1101\/2023.09.05.23295085"},{"key":"10.1016\/j.ejps.2026.107652_bib0174","unstructured":"Koyuncu A. Germany significantly tightens Drug Pricing and Reimbursement Laws | Inside EU Life Sciences. (2022) https:\/\/www.insideeulifesciences.com\/2022\/10\/26\/germany-significantly-tightens-drug-pricing-and-reimbursement-laws\/[Accessed April 5, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jval.2016.12.010","article-title":"The HTA core model\u00ae\u201410 years of developing an international framework to share multidimensional value assessment","volume":"20","author":"Kristensen","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.ejps.2026.107652_bib0120","unstructured":"Les Turner ALS Foundation. Medicare Advantage plans directed to cover treatment for SOD1-ALS. (2024). https:\/\/lesturnerals.org\/medicare-advantage-plans-to-cover-treatment-for-sod1-als\/[Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib176","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care","volume":"16","author":"Luigetti","year":"2020","journal-title":"Ther. Clin. Risk. Manag."},{"key":"10.1016\/j.ejps.2026.107652_bib0049","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2147\/DDDT.S281631","article-title":"Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy","volume":"16","author":"Majeed","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejps.2026.107652_bib184","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40263-025-01204-5","article-title":"Tofersen: A Review in Amyotrophic Lateral Sclerosis Associated with SOD1 Mutations","volume":"39","author":"McGuigan","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejps.2026.107652_bib0058","unstructured":"NC Medicaid, Division of Health Benefits. Givosiran Injection, for Subcutaneous Use (GivlaariTM) HCPCS Code J3490: Billing Guidelines. (2020). https:\/\/medicaid.ncdhhs.gov\/blog\/2020\/01\/28\/givosiran-injection-subcutaneous-use-givlaari%E2%84%A2-hcpcs-code-j3490-billing-guidelines [Accessed April 4, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0047","unstructured":"NC Medicaid, Division of Health Benefits. Patisiran Lipid Complex Injection, for Intravenous Use (OnpattroTM) HCPCS Code J3490: Billing Guidelines. (2018). https:\/\/medicaid.ncdhhs.gov\/blog\/2018\/10\/05\/patisiran-lipid-complex-injection-intravenous-use-onpattrotm-hcpcs-code-j3490-billing-guidelines [Accessed April 4, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0117","unstructured":"Medicines and Healthcare products Regulatory Agency. Tofersen approved by the MHRA to treat rare inherited form of motor neurone disease - GOV.UK. (2025a) https:\/\/www.gov.uk\/government\/news\/tofersen-approved-by-the-mhra-to-treat-rare-inherited-form-of-motor-neurone-disease [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0165","unstructured":"Medicines and Healthcare products Regulatory Agency. mRESVIA RSV vaccine approved to protect patients aged 60 and over. (2025b). https:\/\/www.gov.uk\/government\/news\/mresvia-rsv-vaccine-approved-to-protect-patients-aged-60-and-over [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0069","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C Trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejps.2026.107652_bib0016","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.tips.2022.02.003","article-title":"siRNA drug Leqvio (inclisiran) to lower cholesterol","volume":"43","author":"Migliorati","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2026.107652_bib179","unstructured":"Milliner D.S., Harris P.C., Sas D.J., Cogal A.G., Lieske J.C. Primary Hyperoxaluria Type 1. GeneReviews\u00ae (2025) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1283\/ [Accessed July 16, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0153","unstructured":"Moderna. Moderna Receives Full U.S. FDA approval for COVID-19 vaccine spikevax. (2022). https:\/\/investors.modernatx.com\/news\/news-details\/2022\/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax\/default.aspx [Accessed April 5, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0031","unstructured":"National Centre for Pharmacoeconomics. NCPE Plain English Summary: ONPATTRO, INN-patisiran. (2020). http:\/\/ncpe.ie\/wp-content\/uploads\/2020\/02\/Patisiran-plain-english-summary-24.02.2020.pdf [Accessed October 3, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0041","unstructured":"National Centre for Pharmacoeconomics (NCPE). Cost-effectiveness of patisiran (Onpattro\u00ae) for the treatment of hereditary transthyretin mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (2020). https:\/\/www.ncpe.ie\/wp-content\/uploads\/2019\/01\/Technical-summary-document-patisiran-21.02.2020.pdf."},{"key":"10.1016\/j.ejps.2026.107652_bib0087","unstructured":"National Centre for Pharmacoeconomics. Cost-effectiveness of inclisiran (Leqvio\u00ae) for the treatment of adults with primary. (2022). https:\/\/ncpe.ie\/wp-content\/uploads\/2022\/03\/Inclisiran-Technical-Summary-20051.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0121","unstructured":"National Centre for Pharmacoeconomics. Health Technology Assessment of Inotersen (Tegsedi\u00ae) for the Treatment of Stage 1 or Stage 2 Polyneuropathy in Adult Patients with Hereditary Transthyretin Amyloidosis. (2022). https:\/\/ncpe.ie\/wp-content\/uploads\/2022\/02\/Inotersen-website-summary.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0045","unstructured":"NHS England. MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND V14. (2019). https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2019\/04\/nhs-england-drugs-list-changes-v13.pdf."},{"key":"10.1016\/j.ejps.2026.107652_bib0147","unstructured":"National Institute for Health and Care Excellence (NICE). Project information | Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]. (2024). https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-hst10062 [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0044","unstructured":"National Institute for Health and Care Excellence. Patisiran for treating hereditary transthyretin amyloidosis: highly specialised technologies guidance. (2019a). www.nice.org.uk\/guidance\/hst10."},{"key":"10.1016\/j.ejps.2026.107652_bib0143","unstructured":"National Institute for Health and Care Excellence. Nusinersen for treating spinal muscular atrophy. (2019b). www.nice.org.uk\/guidance\/ta588."},{"key":"10.1016\/j.ejps.2026.107652_bib0129","unstructured":"National Institute for Health and Care Excellence. Inotersen for treating hereditary transthyretin amyloidosis: Highly specialised technologies guidance. (2019c). www.nice.org.uk\/guidance\/hst9."},{"key":"10.1016\/j.ejps.2026.107652_bib0067","unstructured":"National Institute for Health and Care Excellence. Givosiran for treating acute hepatic porphyria: highly specialised technologies guidance. (2021a). www.nice.org.uk\/guidance\/hst16."},{"key":"10.1016\/j.ejps.2026.107652_bib0095","unstructured":"National Institute for Health and Care Excellence. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. (2021b). www.nice.org.uk\/guidance\/ta733."},{"key":"10.1016\/j.ejps.2026.107652_bib0081","unstructured":"National Institute for Health and Care Excellence. Lumasiran for treating primary hyperoxaluria type 1: Highly specialised technologies guidance. (2023a). www.nice.org.uk\/guidance\/hst25."},{"key":"10.1016\/j.ejps.2026.107652_bib0102","unstructured":"National Institute for Health and Care Excellence. Vutrisiran for treating hereditary transthyretin-related amyloidosis. (2023b). www.nice.org.uk\/guidance\/ta868."},{"key":"10.1016\/j.ejps.2026.107652_bib0098","unstructured":"Novartis. Coverage & Support | LEQVIO\u00ae (inclisiran). (2026) https:\/\/www.leqvio.com\/savings-and-support."},{"key":"10.1016\/j.ejps.2026.107652_bib0088","unstructured":"Novartis Ireland. LEQVIO\u00ae (inclisiran): Dosing & administration. (2023) https:\/\/www.leqviohcp.com\/dosing-and-administration [Accessed October 4, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0086","unstructured":"Novartis United States of America. Novartis twice-yearly* Leqvio\u00ae (inclisiran) receives FDA approval for new indication enabling first-line use | Novartis United States of America. (2025) https:\/\/www.novartis.com\/us-en\/news\/media-releases\/novartis-twice-yearly-leqvio-inclisiran-receives-fda-approval-new-indication-enabling-first-line-use [Accessed October 4, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0172","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. Orphan drugs: privilege of \u201cfictitious\u201d added benefit not justified. (2022). https:\/\/www.iqwig.de\/presse\/pressemitteilungen\/pressemitteilungen-detailseite_58496.html [Accessed October 6, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0027","unstructured":"Padda IS, Mahtani AU, Patel P, Parmar M. Small interfering RNA (siRNA) therapy. (2024) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK580472\/[Accessed October 3, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib177","unstructured":"Pan-Canadian Pharmaceutical Alliance. Standard negotiation process. (2026) https:\/\/pcpa-app.ca\/negotiations\/processes-and-frameworks\/standard-negotiation-process [Accessed July 18, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0171","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40273-024-01418-3","article-title":"Evidence following conditional NICE technology appraisal recommendations: a critical analysis of methods, quality and risk of bias","volume":"42","author":"Pijeira Perez","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ejps.2026.107652_bib0017","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17460441.2024.2306843","article-title":"Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy","volume":"19","author":"Plant\u00e9-Bordeneuve","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejps.2026.107652_bib178","doi-asserted-by":"crossref","DOI":"10.1080\/23995270.2026.2642581","article-title":"Givosiran for the treatment of acute hepatic porphyria","volume":"6","author":"Pohl","year":"2026","journal-title":"Future Rare Dis."},{"key":"10.1016\/j.ejps.2026.107652_bib0156","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2026.107652_bib180","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2019.11.072","article-title":"Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors","volume":"75","author":"Preiss","year":"2020","journal-title":"JACC Focus Seminar. J. Am Coll. Cardiol."},{"key":"10.1016\/j.ejps.2026.107652_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.773629","article-title":"Gene Therapy Evidence Generation and Economic Analysis: Pragmatic Considerations to Facilitate Fit-for-Purpose Health Technology Assessment","volume":"10","author":"Qiu","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ejps.2026.107652_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.942976","article-title":"History of development of the life-saving drug \u201cNusinersen\u201d in spinal muscular atrophy","volume":"16","author":"Qiu","year":"2022","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.ejps.2026.107652_bib0084","unstructured":"Regan Lindenboom C, Brodsky J. Alnylam Pharmaceuticals Press Release | Nov 24, 2020 | Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMOTM (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing Solutions to U.S. Payers. (2020) https:\/\/investors.alnylam.com\/press-release?id=25276 [Accessed April 8, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0004","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14737167.2023.2263647","article-title":"Evaluating high-cost technologies \u2013 no need to throw the baby out with the bathwater","volume":"23","author":"Sagoo","year":"2023","journal-title":"Expert Rev. Pharmacoecon. Outcomes. Res."},{"key":"10.1016\/j.ejps.2026.107652_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16140","article-title":"Breaking barriers with tofersen: enhancing therapeutic opportunities in amyotrophic lateral sclerosis","volume":"31","author":"Saini","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejps.2026.107652_bib0173","first-page":"868","article-title":"The evaluation of orphan drugs by the german joint federal committee-an eight-year review","volume":"117","author":"Schulz","year":"2020","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.ejps.2026.107652_bib185","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1136\/jnnp-2022-abn2.6","article-title":"Tofersen in adults with SOD1-ALS: phase 3 VALOR trial and open-label extension results","volume":"93","author":"Shaw","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejps.2026.107652_bib0018","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2026.107652_bib0104","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2026.107652_bib0030","unstructured":"U.S. Food and Drug Administration. Orphan drug designations and Approvals. (2018) https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=371112 [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0085","unstructured":"U.S. Food and Drug Administration. FDA approves add-on therapy to lower cholesterol among certain high-risk adults. (2021) https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults [Accessed October 4, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0021","unstructured":"U.S. Food and Drug Administration. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. (2023) https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene [Accessed October 23, 2025]."},{"key":"10.1016\/j.ejps.2026.107652_bib0105","unstructured":"United Health Care. Oxlumo\u00ae (Lumasiran) and RivflozaTM (Nedosiran) UnitedHealthcare Commercial Medical Benefit Drug Policy. (2024). https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/policies\/comm-medical-drug\/oxlumo.pdf [Accessed April 12, 2026]."},{"key":"10.1016\/j.ejps.2026.107652_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-023-00977-5","article-title":"mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications","volume":"30","author":"Wang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejps.2026.107652_bib0051","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MOG.0000000000000734","article-title":"Novel treatment options for acute hepatic porphyrias","volume":"37","author":"Wang","year":"2021","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.ejps.2026.107652_bib0107","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/nat.2019.0822","article-title":"Population pharmacokinetic\u2013pharmacodynamic modeling of inotersen, an antisense oligonucleotide for treatment of patients with hereditary transthyretin amyloidosis","volume":"30","author":"Yu","year":"2020","journal-title":"Nucleic Acid.Ther."},{"key":"10.1016\/j.ejps.2026.107652_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.carres.2025.109426","article-title":"Advancement of drugs conjugated with GalNAc in the targeted delivery to hepatocytes based on asialoglycoprotein receptor","volume":"552","author":"Zhang","year":"2025","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejps.2026.107652_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejps.2026.107652_bib0009","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.3390\/ijms23052736","article-title":"Current advances in RNA therapeutics for human diseases","volume":"23","author":"Zogg","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:20:49Z","timestamp":1790335249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726002265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":177,"alternative-id":["S0928098726002265"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107652","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107652"}}